MiR-216b-5p inhibits cell proliferation in human breast cancer by down-regulating HDAC8 expression

Mohammad-Nazir Menbari1, Karim Rahimi2, Abbas Ahmadi3

  • 1Cellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.

Life Sciences
|October 13, 2019
PubMed
Abstract

Insights

MicroRNA-216b-5p inhibits breast cancer progression by targeting histone deacetylase 8 (HDAC8). Lower miR-216b-5p levels correlate with advanced cancer, while its overexpression reduces proliferation and metastasis.

Area of Science:

  • Molecular oncology
  • Epigenetics
  • Cancer biology

Background:

  • Histone deacetylase 8 (HDAC8) is overexpressed in breast cancer, but its role in progression is unclear.
  • MicroRNAs (miRs) are key regulators in cancer, influencing oncogenes and tumor suppressors.
  • Understanding miR-216b-5p's interaction with HDAC8 is crucial for breast cancer research.

Purpose of the Study:

  • To investigate the role of miR-216b-5p in regulating HDAC8 expression.
  • To determine the impact of the miR-216b-5p/HDAC8 axis on breast cancer progression.
  • To elucidate the molecular mechanisms underlying HDAC8's function in breast cancer.

Main Methods:

  • Quantitative real-time PCR (qPCR) and Western blotting to assess miR-216b-5p and HDAC8 expression.
  • Cell proliferation, cell cycle, and colony formation assays to evaluate cancer progression.
  • Luciferase reporter assays and HDAC8 knockout vectors to confirm direct targeting and functional impact.

Main Results:

  • Breast cancer tissues and cell lines showed decreased miR-216b-5p and increased HDAC8 levels.
  • Reduced miR-216b-5p correlated with lymph node metastasis and larger tumor size.
  • miR-216b-5p overexpression inhibited proliferation and progression, directly down-regulating HDAC8.

Conclusions:

  • HDAC8 acts as an oncogene promoting breast cancer proliferation and progression.
  • miR-216b-5p suppresses these oncogenic functions by binding to the HDAC8 3'-UTR.
  • The miR-216b-5p/HDAC8 pathway represents a potential therapeutic target for breast cancer.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K